Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key Takeaways
- Early detection depends more on recognizing the right phenotype than on broad, untargeted screening.
- Echocardiography often opens the pathway, but it raises suspicion rather than confirming diagnosis.
- Monoclonal protein testing is the key branch point before a nonbiopsy ATTR pathway becomes credible.
- PYP scintigraphy is most useful when read inside the full workup, not in isolation.
Which Patients Should Trigger ATTR-CM Suspicion
Early detection is most effective when guided by clinical pattern recognition rather than indiscriminate case finding.^1^ Suspicion is most useful in older adults with unexplained wall thickening, heart failure with preserved ejection fraction (HFpEF), conduction disease, atrial arrhythmias, low ECG voltage disproportionate to hypertrophy, or a suggestive extracardiac history. This prospective approach applies the same risk-factor logic to direct workup toward patients most likely to benefit.
What Echocardiography Contributes at the Screening Stage
Echocardiography often serves as the practical entry study because it can surface a phenotype that no longer fits routine remodeling or common heart failure explanations. Its value is in opening the sequence, not settling it. A normal or near-normal study doesn’t exclude early disease, and a suggestive study still requires the broader amyloid workup for interpretation to determine what the phenotype means. In this context, echocardiography is the first step in interpreting the workup, not a substitute for it.
Why Monoclonal Testing Is the Pivotal Branch Point
Monoclonal protein assessment is the pivotal decision point. Serum free light chain testing with serum and urine immunofixation electrophoresis help determine whether ATTR can remain the primary nonbiopsy pathway or whether amyloid light chain (AL) amyloidosis must remain under active consideration. Abnormal monoclonal studies keep AL at the forefront and reduce confidence in an imaging-led ATTR diagnosis, which is why this step is sequenced before heavy reliance on scintigraphy.
Where PYP Scintigraphy and Genetic Testing Fit in the Sequence
Within that sequence, 99mTc-PYP scintigraphy is most informative once phenotype and laboratory context have already raised suspicion because its interpretation depends on the full diagnostic frame rather than uptake alone. TTR genetic testing then helps subtype ATTR once the diagnosis is established or strongly suspected, distinguishing hereditary from wild-type disease and informing family assessment rather than driving the initial detection.
Practical Sequencing Checklist
Work the sequence in order rather than out of turn:
- Is there a compatible phenotype in a patient with the right risk profile?
- Has echocardiography characterized that phenotype?
- Have serum free light chains plus serum and urine immunofixation electrophoresis screened for AL amyloidosis before relying on scintigraphy?
- Is PYP scintigraphy interpreted with single-photon emission computed tomography (SPECT) and in the context of monoclonal results?
- Has TTR genetic testing been arranged to subtype the disease once ATTR-CM is established?
Frequently Asked Questions
Which patients should trigger early ATTR-CM suspicion?
Patients with an unexplained compatible phenotype, especially older adults with wall thickening, HFpEF, conduction disease, atrial arrhythmias, low-voltage mismatch, or a suggestive extracardiac history such as carpal tunnel syndrome.
What does echocardiography contribute at the screening stage?
It often opens the diagnostic pathway by identifying a suspicious phenotype, but it doesn’t confirm ATTR-CM and cannot replace the rest of the amyloid workup.
Why is monoclonal protein testing such an important branch point?
Because abnormal monoclonal studies keep AL amyloidosis in active consideration and weaken the certainty of an imaging-led nonbiopsy ATTR pathway, they are checked before heavy reliance on scintigraphy.
When does PYP scintigraphy add the most value?
It adds the most value when it’s interpreted after phenotype recognition and monoclonal testing have established the right diagnostic context, and with SPECT to confirm myocardial rather than blood-pool uptake.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. PubMed
- Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.